GERON CORP

GERON CORP (GERN) is a publicly listed company on US equity markets.

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

The company reports trailing twelve-month revenue of $191,000 and net loss of $3.64M.

Key metrics include a return on equity of -1.6%, a debt-to-equity ratio of 1.33.

Use FINOTAUR to track GERN's price action, review fundamentals, and stay current with company news — all in one research dashboard.